Patent Issued for Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2) (USPTO 11891638).
In: Gene Therapy Weekly, 2024-03-01, S. 1664-1664
serialPeriodical
Zugriff:
Northwestern University has been issued a patent for active low molecular weight variants of angiotensin converting enzyme 2 (ACE2). These variants of ACE2 have a lower molecular weight than full-length ACE2, allowing them to be filtered through the glomerulus and delivered to the kidney. The patent states that these variants may be useful for treating conditions such as chronic kidney disease, hypertension, scleroderma, and acute stroke. The goal is to develop a form of ACE2 that can easily be delivered to the kidney to combat kidney disease. [Extracted from the article]
Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2) (USPTO 11891638).
|
---|---|
Zeitschrift: | Gene Therapy Weekly, 2024-03-01, S. 1664-1664 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1078-2842 (print) |
Sonstiges: |
|